Medicamento contra obesidade que atua como cavalo de Troia potencializa perda de peso em camundongos

08 de maio de 2026

Reportado por IA

Cientistas desenvolveram um tratamento híbrido contra a obesidade que utiliza sinais de GLP-1 e GIP para entregar um potencializador metabólico diretamente nas células. Testes iniciais em camundongos mostraram uma perda de peso maior e um controle glicêmico melhor do que as terapias padrão. A abordagem visa reduzir efeitos colaterais limitando a ação do medicamento a áreas específicas.

Pesquisadores do Helmholtz Munich criaram o composto ao unir uma molécula baseada em incretina ao lanifibranor, um agonista pan-PPAR. O design funciona como um cavalo de Troia, permitindo que o medicamento adicional entre nas células via receptores de GLP-1 ou GIP antes de ativar interruptores que regulam o metabolismo de gorduras e açúcares dentro do núcleo.

Study finds people who use Ozempic-like drugs for weight loss face added stigma

05 de maio de 2026 Reportado por IA Imagem gerada por IA Verificado

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Cochrane reviews assess GLP-1 drugs for obesity treatment

Three Cochrane reviews commissioned by the World Health Organization evaluate GLP-1 receptor agonists like tirzepatide, semaglutide, and liraglutide for weight loss in people with obesity. The drugs show substantial weight reduction compared to placebo, but researchers note limitations in long-term data and industry funding influences. Side effects such as nausea are common, raising questions about broader access and safety.

India today investigation reveals lax drug norms for weight loss injections

13 de fevereiro de 2026 Reportado por IA

An investigation by India Today highlights how weak enforcement of regulations allows easy access to prescription-only weight-loss drugs in India, leading to increased misuse.

Ásia

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Saúde

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

Saúde

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Researchers at Vanderbilt Health discovered that both popular weight loss drugs and bariatric surgery significantly reduce fat mass while causing modest losses in fat-free mass, including muscle, in patients with obesity. The findings, based on over 3,000 patients, show improvements in overall body composition over 24 months. Maintaining this balance is crucial for long-term health, the study emphasizes.

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

22 de abril de 2026 Reportado por IA Verificado

Researchers in Barcelona report that the lipid drug pemafibrate and the blood-pressure medicine telmisartan reduced diet-induced liver fat in rats and in a zebrafish model of fatty liver disease, with a half-dose combination performing as well as full doses of either drug alone. The work, published in Pharmacological Research, also describes a role for the PCK1 protein in telmisartan’s liver effects and argues that clinical trials would be needed to confirm any benefit in people.

University of Utah researchers identify enzyme PapB that can “lock” GLP-1-like peptides into ring structures

University of Utah scientists report that a radical SAM enzyme known as PapB can join the ends of certain therapeutic peptides to form stable, ring-shaped structures. In experiments described in ACS Bio & Med Chem Au, the enzyme macrocyclized GLP-1-like peptides—including versions containing nonstandard amino acids found in some modern incretin drugs—an approach the researchers say could help make GLP-1 medicines such as semaglutide (Ozempic and Wegovy) more resistant to breakdown.

AI digital twins help manage diabetes and obesity

17 de fevereiro de 2026 Reportado por IA

Silicon Valley startup Twin Health uses AI and wearable sensors as an alternative to expensive GLP-1 drugs for weight management. Retired firefighter Rodney Buckley lost 100 pounds in under a year through the program. His experience highlights a shift toward personalized health tech for chronic conditions.

sexta-feira, 08 de maio de 2026, 01:19h

Medicamento contra obesidade que atua como cavalo de Troia potencializa perda de peso em camundongos

Artigos relacionados

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Cochrane reviews assess GLP-1 drugs for obesity treatment

India today investigation reveals lax drug norms for weight loss injections

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

University of Utah researchers identify enzyme PapB that can “lock” GLP-1-like peptides into ring structures

AI digital twins help manage diabetes and obesity

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Swedish team restores blood sugar control in diabetic mice

Study links Ozempic to lower depression and anxiety risks

Gut reset procedure limits weight regain after stopping Ozempic

Researchers map hindbrain circuit through which hormone FGF21 drives weight loss in obese mice

Study finds prediabetes remission possible without weight loss

GLP-1 weight loss drugs boost premium chocolate sales

Animal study raises new questions about gut effects of SNAC, an ingredient used in oral semaglutide tablets

Scientists identify body's natural off switch for inflammation

New study offers hope for weight loss drugs against alcoholism

Este site usa cookies